Corinne Le Goff
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Moderna, Inc. (MRNA)
Source not stated
Current -
Viatris Inc (VTRS)
Source not stated
Current -
Current
-
Current
-
Start not stated–2024-03-15
-
Start not stated–2024-03-15
Company network
Recorded roles and earnings-call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Imunon, Inc. (IMNN) | Former President and CEO | $148,869 | $148,869 |
| 2024 | Viatris Inc (VTRS) | Chief Commercial Officer | $605,769 | $5,915,394 |
| 2023 | Imunon, Inc. (IMNN) | Former President and CEO | $658,080 | $1,055,814 |
| 2022 | Imunon, Inc. (IMNN) | President & CEO | $264,000 | $883,794 |
| 2021 | Moderna, Inc. (MRNA) | FormerChief Commercial Officer Mr. Meline was hired by the Company on June 8, 2020 and was not an NEO for 2019. Ms. Klinger was hired by the Company on June 1, 2021 and was not an NEO for 2019 or 2020. Dr. Le Goff was hired by the Company on January 19, 2021 and was not an NEO for 2019 or 2020. Dr. Le Goff left the Company on December 17, 2021 but remained a consultant through February 3, 2022. Under her Consulting Agreement, Dr. Le Goff remained eligible for the first tranche of her new hire equity awards (equivalent to 25%); all other tranches were forfeited. | $570,205 | $10,148,448 |
Recent activity
Earnings-call appearances and filed executive appointments or departures, newest first.